Functional Precision Medicine in Pancreatic Cancer
Advanced pancreatic cancer still relies on empirically chosen drug combinations, and these yield response rates of only 20 to 40%. KRAS mutations in pancreatic cancer occur in over 90% of cases, yet responses to KRAS-targeted therapies vary. Functional precision medicine for pancreatic cancer tackles this problem by testing which drugs work in an individual tumor.
A new scientific poster from KYAN Technologies and Memorial Sloan Kettering Cancer Center presents early data on this approach. The team used ex vivo drug sensitivity testing on patient-derived organoids within a CAP/CLIA laboratory. They then assessed the following:
- Feasibility: the test ran on 76% of 37 samples received, and reports were generated within seven business days.
- Concordance: predictions matched prior-line treatment resistance in 78% of cases retrospectively and 80% prospectively.
- RAS-targeted combinations: the platform ranked combinations involving daraxonrasib across KRAS G12D, G12C and G12V models.
These findings are preliminary and the authors call for validation in larger cohorts with diverse KRAS mutational backgrounds.
